Skip to main content
SpringerLink
Log in

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: To determine the maximum tolerated dose (MTD) of intravenous (iv) diflomotecan administered once every 3 weeks, and to characterize the relationship between pharmacokinetics and neutropenic effect, using a semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model. Experimental design: Twenty-four patients received a total of 75 cycles of iv diflomotecan that was administered as 20-min infusion, once every 3 weeks at escalating doses of 2, 4, 5, and 6 mg/m2. Haematological and non-haematological toxicities were evaluated. Plasma concentrations of diflomotecan were measured after the first drug administration. Results: Dose limiting toxicity (DLT) following the first cycle occurred in 12 patients and a total of 16 patients experienced DLT at some point in the trial. During the first cycle of treatment the number of patients in the 5 and 6 mg/m2 dose groups that experienced DLT was 3 of 4, and 3 of 3, respectively. Therefore, the dose of 5 mg/m2 was considered the MTD and the dose of 4 mg/m2 the recommended dose (RD). During the first cycle, 12 patients experienced DLT, six had either infection of haematological toxicity and eight complained of fatigue. The best response was a partial response in one patient treated at the 6 mg/m2 dose level. Disease stabilization was observed in seven patients (four patients treated at 4 mg/m2 and one patient at each dose level of 2, 5, and 6 mg/m2). The remaining patients had all progressive disease. The median time to progression for all patients was 5.9 weeks. Pharmacokinetics of diflomotecan was described with a three-compartmental model. Mean population parameter estimates of the apparent volume of distribution of the central compartment (Vc) increased linearly with body surface area (BSA) as: Vc (L) = 41.5 × (BSA/1.85), and the mean population estimate of the apparent volume of distribution of the shallow compartment was lower in females (29.5 vs 48.8 L). Computer simulations showed the lack of clinical significance of these covariates. The time course of the neutropenic response was adequately described by a semi-mechanistic model that includes cellular processes and drug effects. Conclusions: The MTD and RD after a 20-min iv infusion of diflomotecan every 3 weeks are 4 and 5 mg/m2, respectively. Diflomotecan showed linear pharmacokinetic behaviour and the selected PK/PD model described adequately the time course of neutropenia. The mean model predicted values of nadir and time to nadir after a 20-min iv infusion of 4 mg/m2 of diflomotecan was 0.86 × 109 /L neutrophil cell counts and 11 days, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bailly C (2003) Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 45:91–108

    Article  PubMed  Google Scholar 

  2. Ulukan H, Swaan PW (2002) Camptothecins. A review of their chemotherapeutic potential. Drugs 62:2039–2057

    Article  PubMed  CAS  Google Scholar 

  3. Lavergne O, Demarquay D, Kasprzyk PG, Bigg DC (2000) Homocamptothecins: E-ring modified CPT analogues. Ann N Y Acad Sci 922: 100–111

    Article  PubMed  CAS  Google Scholar 

  4. Versace RW (2003) The silatecans, a novel class of lipophilic camptothecins. Expert Opin Ther Patents 13:751–760

    Article  CAS  Google Scholar 

  5. Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Kasprzyk PG, Bailly Ch, Cámara J, Bigg DCH (2001) The homocampthotecin BN80915 is a highly potent orally active topoisomerase I poison. Anti-Cancer Drugs 12:9–19

    Article  PubMed  CAS  Google Scholar 

  6. Lansiaux A, Facompre M, Wattez N, Hildebrand MP, Bal C, Demarquay D, Lavergne O, Bigg DC, Bailly C (2001) Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 Cells. Mol Pharmacol 60:450–461

    PubMed  CAS  Google Scholar 

  7. Huchet M, Demarquay D, Coulomb H, Kasprzyk P, Carlson M, Lauer J, Lavergne O, Bigg D (2000) The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci 922:303–305

    Article  PubMed  CAS  Google Scholar 

  8. Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJA, Devlin M, van Hooije Ch, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves Ch (2003) Phase I Pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified Camptothecin analogue in adults with solid tumors. Clin Cancer Res 9:4101–4107

    PubMed  CAS  Google Scholar 

  9. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves Ch, Verweij J, McLeod HL (2004) Diflomotecan pharmacokinetics in relation to ABCG2421C>A genotype. Clin Pharmacol Ther 76:38–44

    Article  PubMed  CAS  Google Scholar 

  10. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chaemotherapy-induced myelosupression with parameter consistency across drugs. J Clin Oncol 20:4713–4721

    Article  PubMed  Google Scholar 

  11. Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A (2005) Relationship of systemic exposure to unbound docetaxel and neutropaenia. Clin Pharmacol Ther 77:43–53

    Article  PubMed  CAS  Google Scholar 

  12. Beal SL, Sheiner LB (1992) (eds) NONMEM user’s guides. NONMEM Project Group, University of California at San Francisco, San Francisco

  13. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models; I: models for covariate effects. J Pharmacokinet Biopharm 20:511–528

    Article  PubMed  CAS  Google Scholar 

  14. Jonsson EN, Karlsson MO (1999) Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51–64

    Article  PubMed  CAS  Google Scholar 

  15. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503–12

    Article  PubMed  CAS  Google Scholar 

  16. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171–192

    Article  PubMed  CAS  Google Scholar 

  17. Mould DR, Holford NHG, Schellens JHM, Beijnen JH, Hutson PR, Rosing H, ten Bokkel Huinink WW, Rowinsky EK, Schiller JH, Russo M, Ross G (2002) Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71: 334–348

    Article  PubMed  CAS  Google Scholar 

  18. Schellens JHM, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR (2002) Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. Invest New Drug 20:83–93

    Article  CAS  Google Scholar 

  19. Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 72:265–275

    Article  PubMed  CAS  Google Scholar 

  20. Mathijssen RHJ, Verweij J, de Jongue MJA, Nooter K, Stoter G, Sparreboom A (2002) Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 20:81–87

    Article  PubMed  CAS  Google Scholar 

  21. Solá J, Gay-Feutry C, Massiere F, Peraire C, Obach R, Principe P (2003) In vitro metabolism of diflomotecan in humans. Evaluation of the CYP inhibition potential. Drug Metab Rev 35(Supp 1):51

    Google Scholar 

  22. Baker SD, Verweij J, Rowisnky EK, Donehower RC, Schellens JH, Grochow LB, Sparreboom A (2002) Role of body surface area in dosing investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst 94:1883–1888

    PubMed  CAS  Google Scholar 

  23. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340

    PubMed  CAS  Google Scholar 

  24. Larsen AK, Gilbert C, Chyzak G, Plisov SY, Naguibneva I, Lavergne O, Lesueur-Ginot L, Bigg DCH (2001) Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res 61:2961–2967

    PubMed  CAS  Google Scholar 

  25. Philippart P, Harper L, Chaboteaux C, Decaestecker Ch, Bronckart Y, Gordover L, Leseur-Ginot L, Malonne H, Lavergne O, Bigg DCH, Mendes da Costa P, Kiss R (2000) Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin Cancer Res 6:1557–1562

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by IPSEN group. The authors are grateful to the co-ordinating investigator Prof. M. Marty and to Dr. P. Cottu and Prof. J. Bonneterre for providing the clinical data.

Author information

Authors and Affiliations

  1. Department of Pharmacy, School of Pharmacy, University of Navarra, Pamplona, Spain

    Iñaki F. Trocòniz, María J. Garrido & Cristina Segura

  2. Ipsen Group, Sant Feliu de Llobregat, Barcelona, 08980, Spain

    Josep-María Cendrós, Paola Principe, Concepción Peraire & Rosendo Obach

Authors
  1. Iñaki F. Trocòniz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María J. Garrido
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Segura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Josep-María Cendrós
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Principe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Concepción Peraire
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rosendo Obach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rosendo Obach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trocòniz, I.F., Garrido, M.J., Segura, C. et al. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57, 727–735 (2006). https://doi.org/10.1007/s00280-005-0112-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0112-6

Keywords

Search

Navigation